Oculis Holding Ag · NASDAQ:OCS
Oculis — Shareholder Meeting (June 2025)
22 slides from Oculis's shareholder meeting presentation, Jun 4, 2025
Slide 1: Rethinking Ophthalmology
Rethinking Ophthalmology Annual General Meeting June 4, 2025
Slide 2: Safe Harbor Statements
Safe Harbor Statements Cautionary note on forward-looking statements These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “i
Slide 3: Welcome to the Second Ordinary Shareholders Meeting
Welcome to the Second Ordinary Shareholders Meeting of Oculis Holding AG Anthony Rosenberg Chairperson of the Board of Directors 3
Slide 4: Selected Meeting Participants
Selected Meeting Participants Matthias Staehelin, VISCHER AG Alex Fuhrer, PricewaterhouseCoopers SA Meeting Secretary and Vote Counter Auditors Representative Adrian Severin, PST Legal AG Markus Zwicky, Zwicky & Partner Riad Sherif, MD Independent Proxy Notary, Zug Board Member and CEO of Oculis Hol
Slide 5: Business & Financial Updates
Business & Financial Updates Riad Sherif, MD Sylvia Cheung Chief Executive Officer Chief Financial Officer 5
Slide 6: Business Update
Business Update
Slide 7: Oculis (Nasdaq / XICE: OCS)
Oculis (Nasdaq / XICE: OCS) Global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- ophthalmic diseases with significant unmet medical needs • Global biopharma dual-listed on Nasdaq U.S. and Iceland • Innovative ophthalmology and neuro-ophthalmology candidates with s
Slide 8: First-in-class Candidates Addressing Critical Unmet Medical Needs
First-in-class Candidates Addressing Critical Unmet Medical Needs OCS-01 Privosegtor (OCS-05) Licaminlimab (OCS-02) OPTIREACH® formulation of high Neuroprotective peptoid Antibody fragment technology concentration dexamethasone small molecule of TNFα inhibitor Diabetic Macular Edema Acute Optic Neur
Slide 9: Strong Delivery and Momentum in 2024 and Year-to-Date 2025
Strong Delivery and Momentum in 2024 and Year-to-Date 2025 OCS-01: • 2024: Rapid patient enrollment in DIAMOND Phase 3 trials at industry-leading speed • 2025 April: Completed enrollment in Phase 3 DIAMOND program in DME with >800 patients Privosegtor (OCS-05): • 2024: Strong execution and positive
Slide 10: Explore Advance Expand
Oculis Pipeline Development Strategic Evolution Explore Potential for OCS-05 in Advance Expand multiple additional neuro- ophthalmology and OCS-05 in neuro- neurology conditions OCS-01 could be the first ophthalmology and beyond ever topical treatment in DME, if approved • NAION +$25B4,5 Licaminlima
Slide 11: Advanced and Innovative Pipeline
Advanced and Innovative Pipeline Pre-clinical Phase 1 Phase 2 Phase 3 Next catalysts • DME TLR Q2 2026 OCS-01 DIABETIC MACULAR EDEMA • DME NDA submission 2H 2026 OPTIREACH ® • Ocular surgery NDA submission after DME • FDA meeting 2H 2025 to progress to registrational steps for ACUTE OPTIC NEURITIS a
Slide 12: Financial Update
Financial Update
Slide 13: 2024 Key Financial Data Overview
2024 Key Financial Data Overview • Cash Position YE2024: total cash, cash equivalents and short-term investments of CHF 98.7 million or $109.0 million. Reflecting April 2024 registered direct financing of ~$60 million, and concurrent NASDAQ Iceland listing. • Research and development expenses (70% o
Slide 14: 2025 AGM - Agenda Items and Proposals
2025 AGM - Agenda Items and Proposals
Slide 15: Agenda Items 1-2: Annual Report and Allocation of Results
Agenda Item 1. Approval of the 2024 Annual Report including the 2024 Annual (Statutory) Financial Statements and the 2024 Consolidated Financial Statements The Board proposes the approval of the annual report including the annual financial statements for the business year 2024 and the consolidated f
Slide 16: Agenda Items 3-4: Discharge and Board Re-election
Agenda Item 3. Discharge to the Members of the Board of Directors and the Executive Committee The Board proposes that a full discharge be granted to all members of the Board of Directors and the Executive Committee for their activities in 2024. Agenda Item 4. Re-election of the Chairperson and the o
Slide 17: Agenda Items 5-7: Compensation Committee, Auditors, Proxy
Agenda Item 5. Re-election of the Members of the Compensation Committee The Board of Directors proposes the re-election of Christina Ackermann, Lionel Carnot and Robert K. Warner as members of the Compensation Committee, each until the end of the 2026 Annual General Meeting. Agenda Item 6. Re-electi
Slide 18: Agenda Item 8: Compensation for Non-Executive Board Members
Agenda Item 8. Compensation for the Non-Executive Members of the Board of Directors 8.1. Vote on Total Fixed (Non-Performance-Related) Compensation for Non-Executive Members of the Board of Directors until the end of the Company's 2026 Annual General Meeting The Board of Directors proposes the appro
Slide 19: Agenda Item 9: Compensation for Executive Committee
Agenda Item 9. Compensation for the Members of the Executive Committee 9.1. Vote on Fixed (Non-Performance-Related) Compensation for Members of the Executive Committee payable in 2026 The Board of Directors proposes to approve a total maximum amount of fixed (non-performance- related) compensation f
Slide 20: Agenda Items 10-11: Compensation Report and Capital Band
Agenda Item 10. Non-binding Advisory Vote on the 2024 Compensation Report The Board of Directors proposes the approval on a consultative basis (non-binding advisory vote) of the 2024 Compensation Report. Agenda Item 11. Increase and Amendment of Capital Band The Board of Directors proposes to (i) ad
Slide 21: Agenda Item 12: Conditional Share Capital for Employee Plans
Agenda Item 12. Increase of Conditional Share Capital for Employee Benefit Plans The Board of Directors proposes to (i) adapt the existing first paragraph of article 3c (Conditional Capital Increase for Employee Benefit Plans) of the articles of association pertaining to the conditional capital incr
Slide 22: Thank you
1 Rethinki Oc U | iS | Oohehcinnieay